Clinical Trial Update: Imaging CXCR4 Expression in Subjects With Cancer Using 64 Cu-Plerixafor [EARLY_Phase 1]

View source ↗

Summary

Early-phase 1 trial evaluating imaging CXCR4 expression in cancer patients using the radiolabeled compound 64Cu-plerixafor; the study has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• 64Cu-Plerixafor (plerixafor (radiolabeled copper-64 imaging agent))

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Cancer | EARLY_Phase 1 | Status: TERMINATED